Drug intelligence / Profile preview

CD3-Folate

Development stage: Preclinical
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**CD3-Folate** is a chemically defined bispecific conjugate consisting of an anti-CD3 Fab fragment linked to folate via an oxime bond using unnatural amino acid mutagenesis, designed to target cytotoxic T cells to folate receptor-positive (FR+) tumors. It binds CD3 on T cells and folate receptor alpha (FRα) on cancer cells, promoting T cell-mediated killing through rosette formation and cytotoxicity, with demonstrated efficacy in preclinical models of ovarian and nasopharyngeal cancers, including tumor elimination in xenograft mice even with non-activated PBMCs. Folate conjugation does not alter pharmacokinetics, maintaining a serum half-life of ~60 minutes, and limits off-target effects due to FRα's restricted expression in normal tissues.

Other names: anti-CD3 Fab-folateanti-CD-3 Fab-folateanti-CD 3 Fab-folateUCHT1-FolUCHT-1-FolUCHT 1-FolOKT3-folateOKT-3-folateOKT 3-folateanti-CD3-folateanti-CD-3-folateanti-CD 3-folate

Targets

CD3 (T-cell surface glycoprotein CD3)FOLR1 (FRα)

Beyond the preview

Go deeper on CD3-Folate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD3-Folate.

Explore the full profile